Genome-Wide Methylation Analyses in Glioblastoma Multiforme
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Few studies had investigated genome-wide methylation in glioblastoma multiforme (GBM). Our goals were to study differential methylation across the genome in gene promoters using an array-based method, as well as repetitive elements using surrogate global methylation markers. The discovery sample set for this study consisted of 54 GBM from Columbia University and Case Western Reserve University, and 24 brain controls from the New York Brain Bank. We assembled a validation dataset using methylation data of 162 TCGA GBM and 140 brain controls from dbGAP. HumanMethylation27 Analysis Bead-Chips (Illumina) were used to interrogate 26,486 informative CpG sites in both the discovery and validation datasets. Global methylation levels were assessed by analysis of L1 retrotransposon (LINE1), 5 methyl-deoxycytidine (5m-dC) and 5 hydroxylmethyl-deoxycytidine (5hm-dC) in the discovery dataset. We validated a total of 1548 CpG sites (1307 genes) that were differentially methylated in GBM compared to controls. There were more than twice as many hypomethylated genes as hypermethylated ones. Both the discovery and validation datasets found 5 tumor methylation classes. Pathway analyses showed that the top ten pathways in hypomethylated genes were all related to functions of innate and acquired immunities. Among hypermethylated pathways, transcriptional regulatory network in embryonic stem cells was the most significant. In the study of global methylation markers, 5m-dC level was the best discriminant among methylation classes, whereas in survival analyses, high level of LINE1 methylation was an independent, favorable prognostic factor in the discovery dataset. Based on a pathway approach, hypermethylation in genes that control stem cell differentiation were significant, poor prognostic factors of overall survival in both the discovery and validation datasets. Approaches that targeted these methylated genes may be a future therapeutic goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BT142 G-CIMP status was confirmed by evaluating LINE methylation with the “Global DNA Methylation Assay – LINE-1″ kit (Active Motif), as described36, and by methylation-sensitive restriction digests.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · cited 2×
“Moreover, it appeared that the DNA demethylating agent, 5-deoxy-azacytidine (DAC) was able to reverse methylation and induce gene expression in cancer cells that were marked by both repressive chromatin marks (positive for H3K27me(3)) and methylation, but histone deacetylase inhibitor (HDACi) was not able to re-activa…”
BackgroundIdentification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337 · cited 5×
“Determination of Glioma CpG Island Methylator Phenotype (GCIMP) Status In both the discovery and validation datasets, we found those probes in the Illumina 27 K array that corresponded to the validated GCIMP markers as documented by Noushmehr et al [6].”
BackgroundMethodResultInfluentialControl of Developmental Regulators by Polycomb in Human Embryonic Stem Cells
Lee, T. I., Jenner, R. G., Boyer, L. A., Guenther, M. G., Levine, S. S., Kumar, R. M., Chevalier, B., Johnstone, S. E., Cole, M. F., Isono, K.-I., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.043 · Cited by 2,268 · cited 1×
“To quantify the degree of enrichment in our validated genes, we queried CHIP-seq datasets of H1-hESC (Tier 1) in ENCODE and from published papers [35,36].”
MethodRepetitive DNA and next-generation sequencing: computational challenges and solutions
Treangen, T. J., & Salzberg, S. L. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3117 · Cited by 1,597 · cited 1×
“Despite their abundance and importance in tumorigenesis, the sequences and maps of repetitive elements in the genome have been difficult to ascertain, because repeats created ambiguities in alignment and in genome assembly [13].”
BackgroundRepetitive Elements May Comprise Over Two-Thirds of the Human Genome
de Koning, A. P. J., Gu, W., Castoe, T. A., Batzer, M. A., & Pollock, D. D. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002384 · Cited by 1,112 · cited 2×
“Repetitive elements may comprise over two-thirds of the human genome, and a high proportion of them are retrotransposons, whose expression is normally suppressed by methylation of cytosine [10].”
BackgroundIncreased methylation variation in epigenetic domains across cancer types
Hansen, K. D., Timp, W., Bravo, H. C., Sabunciyan, S., Langmead, B., McDonald, O. G., Wen, B., Wu, H., Liu, Y., Diep, D., et al. (2011) · Nature Genetics · doi:10.1038/ng.865 · Cited by 1,045
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812 · cited 1×
“Nevertheless, in GBM, demethylating agents have not been considered in clinical trials because promoter MGMT methylation is related to temozolomide (TMZ) response [41].”
BackgroundAbundant quantitative trait loci exist for DNA methylation and gene expression in human brain
Gibbs, J. R., van der Brug, M. P., Hernandez, D. G., Traynor, B. J., Nalls, M. A., Lai, S.-L., Arepalli, S., Dillman, A., Rafferty, I. P., Troncoso, J., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000952 · Cited by 769 · cited 1×
“The methylation results using Illumina Methylation 27 K platform were published previously [22].”
MethodUncovering the role of 5-hydroxymethylcytosine in the epigenome
Branco, M. R., Ficz, G., & Reik, W. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3080 · Cited by 766 · cited 1×
“Although it is also a global methylation marker and is closely related to 5m-dC, 5hm-dC is enriched within the gene body, promoters and transcription start site, whereas 5m-dC and LINE1 were primarily located in heterochromatin and repetitive elements [43].”
BackgroundLandscape of Somatic Retrotransposition in Human Cancers
Lee, E., Iskow, R., Yang, L., Gokcumen, O., Haseley, P., Luquette, L. J., Lohr, J. G., Harris, C. C., Ding, L., Wilson, R. K., et al. (2012) · Science · doi:10.1126/science.1222077 · Cited by 762 · cited 1×
“This can lead to transposable elements insertion, and some of them, such as L1, can express their RNAs, which then promote DNA damage, spreading of methylation to promoters and genomic deletions [11,12].”
BackgroundBerman, B. P., Weisenberger, D. J., Aman, J. F., Hinoue, T., Ramjan, Z., Liu, Y., Noushmehr, H., Lange, C. P. E., van Dijk, C. M., Tollenaar, R. A. E. M., et al. (2012) · Nature Genetics · doi:10.1038/ng.969 · Cited by 660 · cited 1×
“The methylome of other cancers had showed concurrent global hypomethylation and gene promoter hypermethylation [20].”
BackgroundGenome-Wide Dna Methylation Profiling Using Infinium ® Assay
Bibikova, M., Le, J., Barnes, B., Saedinia-Melnyk, S., Zhou, L., Shen, R., & Gunderson, K. L. (2009) · Epigenomics · doi:10.2217/epi.09.14 · Cited by 591
Jin, S.-G., Jiang, Y., Qiu, R., Rauch, T. A., Wang, Y., Schackert, G., Krex, D., Lu, Q., & Pfeifer, G. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2023 · Cited by 448 · cited 2×
“5hm-dC is an oxidized product of 5m-dC generated by the a-ketoglutarate-dependent TET dioxygenases [21].”
BackgroundLarge-scale structure of genomic methylation patterns
Rollins, R. A., Haghighi, F., Edwards, J. R., Das, R., Zhang, M. Q., Ju, J., & Bestor, T. H. (2006) · Genome Research · doi:10.1101/gr.4362006 · Cited by 389 · cited 1×
“5% of them in promoters of protein coding genes, demethylation in the repetitive elements may contribute to a significant degree of global hypomethylation in GBM compared to control tissues [42].”
BackgroundDistinct DNA methylation changes highly correlated with chronological age in the human brain
Hernandez, D. G., Nalls, M. A., Gibbs, J. R., Arepalli, S., van der Brug, M., Chong, S., Moore, M., Longo, D. L., Cookson, M. R., Traynor, B. J., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq561 · Cited by 375
Bady, P., Sciuscio, D., Diserens, A.-C., Bloch, J., van den Bent, M. J., Marosi, C., Dietrich, P.-Y., Weller, M., Mariani, L., Heppner, F. L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1016-2 · Cited by 344
A DNA hypermethylation module for the stem/progenitor cell signature of cancer
Easwaran, H., Johnstone, S. E., Van Neste, L., Ohm, J., Mosbruger, T., Wang, Q., Aryee, M. J., Joyce, P., Ahuja, N., Weisenberger, D., et al. (2012) · Genome Research · doi:10.1101/gr.131169.111 · Cited by 292
DNA Methylation Signatures within the Human Brain
Ladd-Acosta, C., Pevsner, J., Sabunciyan, S., Yolken, R. H., Webster, M. J., Dinkins, T., Callinan, P. A., Fan, J.-B., Potash, J. B., & Feinberg, A. P. (2007) · The American Journal of Human Genetics · doi:10.1086/524110 · Cited by 277 · cited 1×
“5 hours of dbGAP brain controls or other post-mortem brain tissues [8,9].”
BackgroundDNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma
Christensen, B. C., Smith, A. A., Zheng, S., Koestler, D. C., Houseman, E. A., Marsit, C. J., Wiemels, J. L., Nelson, H. H., Karagas, M. R., Wrensch, M. R., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq497 · Cited by 255
Cadieux, B., Ching, T.-T., VandenBerg, S. R., & Costello, J. F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1547 · Cited by 234 · cited 1×
“One study that measured 5-methylcytosine content using a methyl acceptance assay in one epileptic specimen and 10 GBM tissues showed global hypomethylation in tumors [19].”
MethodRegional Activation of the Cancer Genome by Long-Range Epigenetic Remodeling
Bert, S. A., Robinson, M. D., Strbenac, D., Statham, A. L., Song, J. Z., Hulf, T., Sutherland, R. L., Coolen, M. W., Stirzaker, C., & Clark, S. J. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.006 · Cited by 201 · cited 1×
“versus those chromatin alterations that affect hypermethylation [37].”
BackgroundGenome-wide DNA methylation profiles in hepatocellular carcinoma
Shen, J., Wang, S., Zhang, Y.-J., Kappil, M., Wu, H.-C., Kibriya, M. G., Wang, Q., Jasmine, F., Ahsan, H., Lee, P.-H., et al. (2012) · Hepatology · doi:10.1002/hep.25569 · Cited by 196 · cited 16×
“3-uM forward and 59 biotinylated reverse primers, using the cycling conditions and amplifications as outlined previously [31].”
MethodResultSelf-citationA microarray-based DNA methylation study of glioblastoma multiforme
Martinez, R., Martin-Subero, J. I., Rohde, V., Kirsch, M., Alaminos, M., Fernández, A. F., Ropero, S., Schackert, G., & Esteller, M. (2009) · Epigenetics · doi:10.4161/epi.9130 · Cited by 173
Long Interspersed Element–1 (LINE-1): Passenger or Driver in Human Neoplasms?
Rodić, N., & Burns, K. H. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003402 · Cited by 164 · cited 1×
“This can lead to transposable elements insertion, and some of them, such as L1, can express their RNAs, which then promote DNA damage, spreading of methylation to promoters and genomic deletions [11,12].”
BackgroundDNA methylation predicts recurrence from resected stage III proximal colon cancer
Ahn, J. B., Chung, W. B., Maeda, O., Shin, S. J., Kim, H. S., Chung, H. C., Kim, N. K., & Issa, J. J. (2011) · Cancer · doi:10.1002/cncr.25737 · Cited by 154
Christians, A., Hartmann, C., Benner, A., Meyer, J., von Deimling, A., Weller, M., Wick, W., & Weiler, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033449 · Cited by 146 · cited 2×
“MGMT Methylation For MGMT methylation status in the discovery dataset, we chose pyrosequencing as the analytical method, because previous studies showed that it provided the best prognostic value, cost effectiveness and ease of use [29].”
BackgroundMethodCpG Island Hypermethylation in Human Astrocytomas
Wu, X., Rauch, T. A., Zhong, X., Bennett, W. P., Latif, F., Krex, D., & Pfeifer, G. P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3631 · Cited by 136
Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis
Laffaire, J., Everhard, S., Idbaïh, A., Crinière, E., Marie, Y., de Reyniès, A., Schiappa, R., Mokhtari, K., Hoang‐Xuan, K., Sanson, M., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq110 · Cited by 133 · cited 1×
“Thus our results supported previous reports of excellent validations of this methylation array technology using pyrosequencing [3,31].”
ResultThe CpG island methylator phenotype in colorectal cancer: Progress and problems
Hughes, L., Bakker, C. A. J. K.-D., Smits, K. M., van den Brandt, P. A., Jonkers, D. M. A. E., Ahuja, N., Herman, J. G., Weijenberg, M. P., & van Engeland, M. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.10.005 · Cited by 127 · cited 1×
“Moreover, as one recent systematic review pointed out, there has been a lack of consensus on the precise definition of CIMP in cancers [38].”
BackgroundOrzan, F., Pellegatta, S., Poliani, P. L., Pisati, F., Caldera, V., Menghi, F., Kapetis, D., Marras, C., Schiffer, D., & Finocchiaro, G. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01132.x · Cited by 124 · cited 1×
“PRC2 was up-regulated in glioblastoma stem-like cells [39].”
BackgroundWoo, H. D., & Kim, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034615 · Cited by 123 · cited 1×
“Analysis of LINE1 is widely used as a marker of global cytosine methylation level [10,18].”
BackgroundOhka, F., Natsume, A., Motomura, K., Kishida, Y., Kondo, Y., Abe, T., Nakasu, Y., Namba, H., Wakai, K., Fukui, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023332 · Cited by 116 · cited 1×
“Thus, as reported previously, we used 14% as the threshold to distinguish unmethylated from methylated MGMT promoter in a given tumor [15].”
MethodHåvik, A. B., Brandal, P., Honne, H., Dahlback, H.-S. S., Scheie, D., Hektoen, M., Meling, T. R., Helseth, E., Heim, S., Lothe, R. A., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-36 · Cited by 114 · cited 1×
“Seven CpG sites in the promoter region of MGMT were selected based on previous validations, with a Qiagen kit (PM00149702) [30].”
MethodGenome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer
Estécio, M. R. H., Gallegos, J., Vallot, C., Castoro, R. J., Chung, W., Maegawa, S., Oki, Y., Kondo, Y., Jelinek, J., Shen, L., et al. (2010) · Genome Research · doi:10.1101/gr.107318.110 · Cited by 89
SINE Retrotransposons Cause Epigenetic Reprogramming of Adjacent Gene Promoters
Estécio, M. R. H., Gallegos, J., Dekmezian, M., Lu, Y., Liang, S., & Issa, J.-P. J. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0351 · Cited by 83
Wang, Y., Gu, J., Roth, J. A., Hildebrandt, M. A. T., Lippman, S. M., Ye, Y., Minna, J. D., & Wu, X. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3273 · Cited by 82
Sher, F., Boddeke, E., Olah, M., & Copray, S. C. V. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040399 · Cited by 77 · cited 2×
“Moreover, it appeared that the DNA demethylating agent, 5-deoxy-azacytidine (DAC) was able to reverse methylation and induce gene expression in cancer cells that were marked by both repressive chromatin marks (positive for H3K27me(3)) and methylation, but histone deacetylase inhibitor (HDACi) was not able to re-activa…”
BackgroundMethodWang, S., Dorsey, T. H., Terunuma, A., Kittles, R. A., Ambs, S., & Kwabi‐Addo, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037928 · Cited by 77
Wu, H., Delgado‐Cruzata, L., Flom, J. D., Perrin, M. C., Liao, Y., Ferris, J. S., Santella, R. M., & Terry, M. B. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs201 · Cited by 75
Self-citationQuinlivan, E. P., & Gregory, J. F. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn534 · Cited by 59 · cited 1×
“We modified a previously published method by adding determination of 5hm-dC levels, using [(15)N3]-5m-dC as the internal standard for 5hm-dC and [(15)N3]-dC as the internal standard for dC [24].”
MethodGlobal hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B1exposure
Zhang, Y., Wu, H., Yazıcı, H., Yu, M., Lee, P., & Santella, R. M. (2012) · World Journal of Hepatology · doi:10.4254/wjh.v4.i5.169 · Cited by 52
Wu, H., Wang, Q., Yang, H., Tsai, W., Chen, C., & Santella, R. M. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs160 · Cited by 45 · cited 1×
“We compared LINE1, 5m-dC and 5hm-dC levels among methylation classes using the non-parametric Kruskal-Wallis Test, as prior analyses had shown that these markers were not normally distributed [26].”
MethodSelf-citationStricker, I., Tzivras, D., Nambiar, S., Wulf, J., Liffers, S., Vogt, M., Verdoodt, B., Tannapfel, A., & Mirmohammadsadegh, A. (2012) · PubMed · Cited by 40
Genome-Wide Divergence of DNA Methylation Marks in Cerebral and Cerebellar Cortices
Xin, Y., Chanrion, B., Liu, M.-M., Galfalvy, H., Costa, R., Ilievski, B., Rosoklija, G., Arango, V., Dwork, A. J., Mann, J. J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011357 · Cited by 39 · cited 1×
“5 hours of dbGAP brain controls or other post-mortem brain tissues [8,9].”
BackgroundZhang, Y., Shu, J., Si, J., Shen, L., Estecio, M. R., & Issa, J. J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks429 · Cited by 33
Pyrosequencing of IDH1 and IDH2 Mutations in Brain Tumors and Non-neoplastic Conditions
Cykowski, M. D., Allen, R. A., Fung, K.-M. A., Harmon, M. A., & Dunn, S. T. (2012) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31825d802b · Cited by 21 · cited 1×
“Polymerase chain reaction (PCR) and pyrosequencing assays were performed as previously described [28].”
Method
Cited by
Insulator dysfunction and oncogene activation in IDH mutant gliomas
Flavahan, W. A., Drier, Y., Liau, B. B., Gillespie, S. M., Venteicher, A. S., Stemmer-Rachamimov, A. O., Suvà, M. L., & Bernstein, B. E. (2016) · Nature · doi:10.1038/nature16490 · Cited by 1,288
Circulating biomarkers for gliomas
Westphal, M., & Lamszus, K. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.171 · Cited by 181
Lee, W., Johnson, J., Gough, D. J., Donoghue, J., Cagnone, G. L. M., Vaghjiani, V, Brown, K. A., Johns, T. G., & St. John, J. C. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.34 · Cited by 129
“However, cancer cells, such as those giving rise to Glioblastoma multiforme, the most aggressive malignant primary brain tumour,(18,19) are extensively DNA methylated.(20) When induced to differentiate, they fail to increase mtDNA copy number and continue to express NESTIN, MUSASHI1 and CD133.”
BackgroundPark, A. K., Kim, P., Ballester, L. Y., Esquenazi, Y., & Zhao, Z. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy120 · Cited by 111
Brigliadori, G., Foca, F., Dall’Agata, M., Rengucci, C., Melegari, E., Cerasoli, S., Amadori, D., Calistri, D., & Faedi, M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2116-y · Cited by 70
“Methylation status of each CpG island in the promoter region of many genes like MGMT have already been investigated [24] to evaluate their role in gene silencing.”
Background
Metadata
- Authors
- Lai, R. K., Chen, Y., Guan, X., Nousome, D., Sharma, C., Canoll, P., Bruce, J., Sloan, A. E., Cortes, E., Vonsattel, J.-P., Su, T., Delgado-Cruzata, L., Gurvich, I., Santella, R. M., Ostrom, Q., Lee, A., Gregersen, P., & Barnholtz-Sloan, J.
- Affiliations
- University of Southern California (US)
- Case Comprehensive Cancer Center (US)
- Columbia University (US)
- University Hospitals Cleveland Medical Center (US)
- Herbert Irving Comprehensive Cancer Center (US)
- North Shore University Hospital (US)
- Corresponding author
- Lai, Rose K.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-21
- Volume
- 9
- Issue
- 2
- Pages
- e89376
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3931727
- OpenAlex
- W2036863866
- Cited by
- 54
- References
- 46
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 9 · 2020: 6 · 2019: 5 · 2018: 5 · 2017: 8 · 2016: 4 · 2015: 9
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CUNY Academic Works (City University of New York) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institutes of Health
- National Cancer Institute (K07CA127468, R01CA139020, R01CA139020-27064, P30CA043703, P30CA014089)
- National Institute of Environmental Health Sciences (P30ES009089)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- glioblastoma, DNA methylation, differentially methylated genes, promoter hypermethylation, promoter hypomethylation, LINE-1 retrotransposons, 5-methylcytosine, 5-hydroxymethylcytosine, immune pathways, stem cell differentiation, prognostic factors, overall survival, epigenetic therapy targets
- MeSH terms
- Adult, Aged, Aged, 80 and over, Brain, Brain Neoplasms, Female, Glioblastoma, Humans, Male, Middle Aged, Promoter Regions, Genetic, CpG Islands, DNA Methylation, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.